Table 1a:
Clinical characteristics at diagnosis of AAV-GN and outcome of all patients, and of whose who developed or did not develop ESKD.
| Clinical characteristics | All (n = 152) | ESKD (n = 59) | No ESKD (n = 93) | P-value |
|---|---|---|---|---|
| Male, n (%) | 84 (55.3) | 33 (55.0) | 51 (55.4) | .89 |
| Age, years | 63.8 (51.3–70.8) | 66 (53.7–74.8) | 62.0 (47.9–70.0) | .03 |
| Serum creatinine, mg/dL | 3.9 (2.45–7.0) | 6.0 (4.0–8.2) | 3.1 (2.0–4.7) | .001 |
| Proteinuria g/day, mean (SD) | 1.53 (1.66) | 2.05 (1.96) | 1.24 (1.29) | .005 |
| Hemoglobin, g/dL | 9.00 (8.1–10.4) | 8.7 (8.2–9.8) | 9.3 (8.1–10.7) | .048 |
| eGFR, mL/min/1.73 m2 | 13.0 (7.0–26.0) | 7.7 (6.0–13.6) | 18.0 (11.2–32.5) | .0001 |
| eGFR <15 mL/min/1.73 m2, n (%) | 86 (56.5) | 46 (77.9) | 40 (43.0) | .000023 |
| GPA, n (%) | 55 (36.2) | 20 (33.8) | 35 (37.6) | .64 |
| MPA, n (%) | 66 (43.4) | 25 (42.3) | 41 (44.0) | .72 |
| Renal-limited vasculitis, n (%) | 30 (19.7) | 14 (23.7) | 16 (17.2) | .32 |
| MPO-ANCA, n (%)a | 77 (50.6) | 28 (47.4) | 49 (52.6) | .39 |
| PR3-ANCA, n (%) | 49 (32.2) | 20 (33.8) | 29 (31.1) | .72 |
| BVAS | 15.0 (13.0–19.0) | 15 (12.5–19.0) | 15.0 (13.0–19.0) | .95 |
| MPO-ANCA and PR3-ANCA, n (%) | 3 (1.9) | 1 (1.7) | 2 (2.1) | .84 |
| Cutaneous involvement, n (%) | 14 (9.2) | 5 (8.4) | 9 (9.6) | .06 |
| Joint involvement, n (%) | 36 (23.6) | 15 (25.4) | 21 (22.5) | .48 |
| Ear nose and throat involvement, n (%) | 25 (16.4) | 8 (26.6) | 17 (18.2) | .44 |
| Pulmonary involvement, n (%) | 28 (18.42) | 8 (13.5) | 20 (21.5 | .21 |
| Gastrointestinal involvement, n (%) | 1 (0.6) | 1 (1.6) | 0 | |
| Hypertension, n (%) | 80 (52.6) | 39 (66.1) | 41 (44.5) | .008 |
| Follow-up, months | 46.9 (12.8–119.0) | 11.3 (3.3–51.9) | 74.1 (33.4–140.9) | <.00001 |
| Induction therapy | ||||
| MP pulses, n (%) | 136 (89.4) | 53 (89.8) | 83 (89.2) | .909 |
| Immunosuppressantsb, n (%) | 102 (67.1) | 37 (62.7) | 65 (69.8) | .358 |
| Plasma exchangec, n (%) | 19 (12.4) | 8 (13.5) | 11 (11.8) | .753 |
| Maintenance therapy | ||||
| Prednisoned, n (%) | 41 (27.0) | 13 (22.0) | 28 (30.1) | .27 |
| Immunosuppressante, n (%) | 69 (45.4) | 16 (27.1) | 53 (57.0) | .0003 |
| Deaths, n (%) | 39 (25.4) | 20 (33.9) | 19 (20.4) | .06 |
If not otherwise specified, data are reported as median and IQR.
aData non available for 11 patients.
bEighty-three patients received cyclophosphamide (32 developed ESKD); 18 received rituximab (5 developed ESKD); 1 received methotrexate.
cFifteen patients received plasma exchange after an immunosuppressant agent.
dPatients who have received only prednisone as maintenance therapy for at least 6 months.
ePatients treated with steroid for at least 6 months and immunosuppressant. Forty-four patients received azathioprine at the beginning of maintenance therapy; 11 patients received mycophenolate mofetil; 12 patients received rituximab; 1 received methotrexate; 1 received cyclophosphamide.
P < .05 is considered significant (Pearson chi-square test for categorical variables, analysis of variance for continuous variables) and is shown in bold.
MP, methylprednisolone.